JNJ

188.94

-0.04%↓

ABT

123.73

-0.97%↓

TMO

568.84

+1.99%↑

ISRG

536.46

+1.27%↑

DHR

216.04

+0.59%↑

JNJ

188.94

-0.04%↓

ABT

123.73

-0.97%↓

TMO

568.84

+1.99%↑

ISRG

536.46

+1.27%↑

DHR

216.04

+0.59%↑

JNJ

188.94

-0.04%↓

ABT

123.73

-0.97%↓

TMO

568.84

+1.99%↑

ISRG

536.46

+1.27%↑

DHR

216.04

+0.59%↑

JNJ

188.94

-0.04%↓

ABT

123.73

-0.97%↓

TMO

568.84

+1.99%↑

ISRG

536.46

+1.27%↑

DHR

216.04

+0.59%↑

JNJ

188.94

-0.04%↓

ABT

123.73

-0.97%↓

TMO

568.84

+1.99%↑

ISRG

536.46

+1.27%↑

DHR

216.04

+0.59%↑

Search

AnaptysBio Inc

Open

SectorHealthcare

36 -3.49

Overview

Share price change

24h

Current

Min

35.2

Max

37.43

Key metrics

By Trading Economics

Income

699K

-39M

Sales

-5.5M

22M

Profit margin

-173.517

Employees

136

EBITDA

9.2M

-18M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+79.96% upside

Dividends

By Dow Jones

Next Earnings

3 lis 2025

Market Stats

By TradingEconomics

Market Cap

300M

1B

Previous open

39.49

Previous close

36

News Sentiment

By Acuity

50%

50%

168 / 373 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 paź 2025, 23:32 UTC

Hot Stocks

Stocks to Watch: Amazon, Reddit, SPS Commerce

30 paź 2025, 23:02 UTC

Earnings

AIA Group 3Q Value of New Business Grew

30 paź 2025, 23:45 UTC

Market Talk

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30 paź 2025, 23:00 UTC

Earnings

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30 paź 2025, 22:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

30 paź 2025, 22:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30 paź 2025, 22:56 UTC

Market Talk

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30 paź 2025, 22:35 UTC

Earnings

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30 paź 2025, 22:35 UTC

Earnings

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30 paź 2025, 22:31 UTC

Earnings

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30 paź 2025, 22:29 UTC

Earnings

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30 paź 2025, 22:27 UTC

Earnings

Minas Buenaventura 3Q EPS 66c >BVN

30 paź 2025, 22:27 UTC

Earnings

Minas Buenaventura 3Q Rev $431M >BVN

30 paź 2025, 22:27 UTC

Earnings

Minas Buenaventura 3Q Net $179M >BVN

30 paź 2025, 22:16 UTC

Market Talk
Earnings

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30 paź 2025, 22:14 UTC

Earnings

Review & Preview: A Tech Earnings Storm -- Barrons.com

30 paź 2025, 22:00 UTC

Earnings
Acquisitions, Mergers, Takeovers

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30 paź 2025, 21:39 UTC

Earnings

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 paź 2025, 21:26 UTC

Earnings

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 paź 2025, 21:14 UTC

Market Talk
Earnings

Apple Sees Record Quarterly Services Revenue -- Market Talk

30 paź 2025, 21:09 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

30 paź 2025, 21:09 UTC

Market Talk
Earnings

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30 paź 2025, 21:04 UTC

Earnings

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30 paź 2025, 21:03 UTC

Earnings

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30 paź 2025, 21:03 UTC

Earnings

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30 paź 2025, 21:00 UTC

Earnings

Eldorado Gold Skouries on Track for 1Q of 2026

30 paź 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q Adj EPS 41c >EGO

30 paź 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q Rev $434.7M >EGO

30 paź 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q Net $56M >EGO

30 paź 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q EPS 27c >EGO

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

79.96% upside

12 Months Forecast

Average 65 USD  79.96%

High 90 USD

Low 20 USD

Based on 12 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

10

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

19.25 / 21.135Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

168 / 373 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
help-icon Live chat